Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term nemolizumab safety and efficacy study in moderate-to-severe atopic dermatitis
NL-OMON54779Phase 3Recruiting
- Sponsor
- Galderma
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, double-blind trial of nemolizumab in atopic dermatitis (AD) (2 arms), sponsored by Galderma. Primary endpoints: Incidence and severity of treatment-emergent adverse events, Incidence of serious treatment-emergent adverse events and 1 more. Started Jun 2021; status: recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NL-OMON54779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54779.